Reddit
Merck and Moderna's Personalized mRNA Cancer Vaccine Cleared Phase 3, the First Ever for a Neoantigen Therapy
On 2026-08-19 Merck and Moderna reported that intismeran autogene plus Keytruda met both the primary endpoint (recurrence-free survival) and a key secondary endpoint (distant metastasis-free survival) in INTerpath-001, a 1,137-patient trial in fully resected stage IIB-IV cutaneous melanoma, against Keytruda alone. This is the first positive Phase 3 for an individualized neoantigen therapy and for any mRNA-based cancer treatment, with no new safety signals and a regulatory submission planned. MRNA stock rose over 110%, and the r/singularity thread (1,010 upvotes) is worth reading for the top-voted correction that this is a therapy for a specific cancer a patient already has, not a cure.
Source
↳ Follow the thread